Share:

Top Back to top

My paper of the Month - Orca-T vs allogeneic haematopoietic stem cell transplantation

Research

Publication Full Title: Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial

Journal: Blood

Published: 12 March 2026

Publication Link: https://ashpublications.org/blood/article/147/11/1168/557305/Orca-T-vs-allogeneic-hematopoietic-stem-cell

Comment by: 
Rachele De Domenico, Hematology resident at University of Brescia and ASST Spedali Civili di Brescia, Italy, currently fellow at Institut Català d'Oncologia, Barcelona, Spain

Alberto Mussetti, Director Hematopoietic Cell Transplant/Cell Therapy Unit - Institut Català d’Oncologia - Campus Salut Bellvitge Comprehensive Cancer Center, Barcelona, Spain


Summary

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative strategy for hematological malignancies, driven by the graft-versus-tumor (GVT) effect mediated by donor T cells. However, donor T-cell alloreactivity also instigates graft-versus-host disease (GVHD), which remains the leading cause of non-relapse mortality (NRM) after allo-HCT [1].

Orca-T is a precision-engineered cellular graft designed to address this issue [2].

The Precision-T trial is a multicenter, randomized, phase 3 study evaluating adults with acute leukemia or myelodysplastic syndrome (MDS) undergoing myeloablative allo-HCT from HLA-matched donors. Patients were randomized to receive either Orca-T with single-agent tacrolimus or a conventional, unmanipulated peripheral blood graft with standard tacrolimus and methotrexate (Tac/MTX) as GVHD prophylaxis [2].

At a median follow-up of nearly 1 year, Orca-T met its primary endpoint, demonstrating a significantly superior chronic GVHD-free survival (cGFS) compared to the control arm (78.0% vs. 38.4%; P < .001). Notably, NRM was  lower in the Orca-T cohort (3.4% vs. 13.2%; P = .03). Orca-T also reduced the incidence of moderate-to-severe chronic GVHD, serious infections, and immunosuppression-related adverse events, while ensuring robust engraftment and immune reconstitution. No significant differences were observed between the two arms regarding relapse rates, disease-free survival (DFS), or overall survival (OS) [2].

Comment

The pivotal role of donor T cells in graft-versus-host disease (GVHD) was established through pioneering experimental studies in murine models in the late 1970s and early 1980s [3, 4]. 

Strategies to control donor T-cell alloreactivity have evolved from broad ex vivo T-cell depletion [5]., through pharmacological in vivo modulation with antithymocyte globulin (ATG) [6] and post-transplant cyclophosphamide (PTCy) [7], toward increasingly precise graft engineering based on the rational selection of donor T-cell subsets [8].

The study by Meyer et al. provides the first clinical evidence that selective T-cell manipulation of the graft can translate into improved transplant outcomes, reducing both GVHD and non-relapse mortality (NRM) compared with conventional allo-HCT.

However, several important considerations should be noted. The median follow-up was less than one year, and therefore the long-term effects of Orca-T on GVHD, relapse, and survival remain to be established. Moreover, enrollment was restricted to HLA-matched transplantation after myeloablative conditioning and to a limited number of conditioning, leaving the efficacy of Orca-T with other commonly used regimens, such as treosulfan-based conditioning, largely unexplored. Furthermore, the conventional transplantation arm used tacrolimus plus methotrexate as the sole GVHD prophylaxis strategy, thus precluding direct comparison with other widely used approaches, particularly ATG- or PTCy-based regimens. 

Overall, the study provides initial evidence that precision graft manipulation may enable a more personalized and immunologically precise approach to allo-HCT. Nevertheless, further investigation is needed to determine whether these promising results can be extended to other hematologic and immunologic diseases.

In conclusion, Orca-T represents a major clinical advancement driven by a robust biological rationale. This strategy demonstrates that separating GVT from GVHD may be clinically achievable through accurate donor T-cell selection, granting engraftment and immune reconstitution with minimal risk of graft failure, and reducing the rate of GVHD, ultimately leading to an overall improvement in transplant outcomes.

References

  1. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10(3):213-221. doi:10.1038/nrc2804
  2. Meyer EH, Salhotra A, Gandhi AP, et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026;147(11):1168-1177. doi:10.1182/blood.2025031313
  3. Korngold R, Sprent J. Lethal GVHD across minor histocompatibility barriers: nature of the effector cells and role of the H-2 complex. Immunol Rev. 1983; 71:5-29. doi:10.1111/j.1600-065x.1983.tb01066.x
  4. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150. doi:10.1038/nm915
  5. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339(17):1186-1193. doi:10.1056/NEJM199810223391702
  6. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947. doi:10.1182/blood.v98.10.2942
  7. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650. doi:10.1016/j.bbmt.2008.03.005
  8. Bleakley M, Heimfeld S, Jones LA, et al. Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant. 2014;20(5):705-716. doi:10.1016/j.bbmt.2014.01.032